Clinical efficacy of kantaka panchamoola in Shukra Dushti

Phytochemical and Clinical efficacy of Kantaka Panchamoola in the management of Shukra Dushti

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/03/041228

Enrollment

Registered

2022-03-21

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N461- Oligospermia Health Condition 2: N468- Other male infertility

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: a) Male Patients between the age group of 21-50 years of age. b) Willing and able to participate in the study for 90 days. c) Patients suffering from semen disorders over the past 6 months or more. d) Patients with History of Infertility for the past 3 years. f) Patients with lack of libido / sexual desire/ Impotence/ Erectile Dysfunction. g) Patients with Difficulty in ejaculation of semen. h) Patients ejaculating little quantity of semen after painful coitus.

Exclusion criteria

Exclusion criteria: a) Men with a total sperm concentration of b) Patients having a history of congenital deformity in genitals. c) Patients with evidence of Malignancy. d) Patients having any type of surgery of genitals. e) Known case of serious hepatic, cardiac or kidney diseases. f) Patients having history of Chronic Fever. g) Patient having any sexual transmitted diseases. h) Patients on prolonged medication with corticosteroids, antidepressants, anticholinergics, immunosuppressant, etc. or any other drugs that may have an influence on the outcome of the study. i) Patients with poorly controlled hypertension (systolic >140 and diastolic >90 mm of Hg) despite of antihypertensive agents. j) Hypersensitivity to any of the trial drugs or their ingredients. k) Patients who have completed participation in any other clinical trial drugs or their ingredients.

Design outcomes

Primary

Measure	Time frame
The Expected Primary End point is improvement in the semen parameters. levels from baseline (Day 1) after 90 days of therapyTimepoint: 3 months	—

Secondary

Measure	Time frame
The Expected secondary outcome is the safety and efficacy of the therapy under investigation. Safety will be assessed based on the adverse events recorded during the studyTimepoint: 3 months	—

Countries

India

Contacts

Public ContactDr Rajesh Sharma

A and U Tibbia College

rajsakshi.sharma@gmail.com9868092250

Outcome results